1-3 of 3
Ilir Maraj
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Panobinostat, a Novel Histone Deacetylase (HiDAC) Inhibitor Enhances the Anti-Tumor Activity of Bortezomib (BTZ) In Rituximab-Chemotherapy Sensitive and Resistant Lymphoma Cell Lines

Francisco J. Hernandez-Ilizaliturri, MD, Cory Mavis, BSc, MSc, Ilir Maraj, Mohammad Muhsin Chisti, John Gibbs, MD, Myron S. Czuczman, MD
Journal: Blood
Blood (2010) 116 (21): 3936.
https://doi.org/10.1182/blood.V116.21.3936.3936
Published: 2010
Journal Articles

The DAC Inhibitor, LBH589, Is Highly Effective in Both Rituximab-Sensitive and Rituximab-Resistant Lymphomas and Enhances the Anti-Tumor Activity of Bortezomib, Other Chemotherapy Agents, and Anti-CD20 Monoclonal Antibodies.

Francisco J Hernandez-Ilizaliturri, MD, Cory Marvis, MS, Ilir Maraj, MD, Mohammad M Chisti, MD, John Gibbs, MD, Myron S Czuczman
Journal: Blood
Blood (2009) 114 (22): 2715.
https://doi.org/10.1182/blood.V114.22.2715.2715
Published: 2009
Journal Articles

The DAC Inhibitor LBH589 Is Highly Effective in Both “Therapy”-Sensitive and -Resistant Lymphomas and Enhances the Anti-Tumor Activity of Chemotherapy Agents, Monoclonal Antibodies, and Bortezomib

Ilir Maraj, MD, Francisco J. Hernandez-Ilizaliturri, MD, Mohammad M Chisti, MD, Myron S. Czuczman, MD
Journal: Blood
Blood (2008) 112 (11): 4984.
https://doi.org/10.1182/blood.V112.11.4984.4984
Published: 2008